

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:



Date: 10.21.99

By: *[Signature]*

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Woodle, et al.

SERIAL No.: 09/139,058

FILED: August 24, 1998

FOR: METHOD OF TREATMENT OF INFECTED
TISSUES

EXAMINER: Kishore

ART UNIT: 1615

10

Terminal Disclaimer

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Sequus Pharmaceuticals, Inc., Assignee of

- ☐ an undivided share of the entire right, title, and interest
☒ the entire right, title and interest

in the above-identified patent application by virtue of an Assignment recorded in the U.S. Patent and Trademark Office at Reel 7709, Frame 0514, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154 to §156 and §173, as presently shortened by any terminal disclaimer, of

10/28/1999 RHARRON 00000007 040531 09139058
Sale Ref: 00000007 DAB: 040531 09139058
01 FC:115 110.00 CH
148

U.S. Patent No. 5,213,804 Issued May 25, 1993

and

U.S. Patent No. 5,013,556 Issued May 7, 1991.

The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the above-listed patents and/or patent applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 USC §154 to §156 and §173 of the above-listed patents and/or applications, as presently shortened by any terminal disclaimer, in the event that said patent(s)/application(s) later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

1. Authority of Undersigned

The undersigned is an attorney or agent of record.

2. Fee Payment

- ☒ A check for \$110.00 covering the Terminal Disclaimer fee under 37 CFR 1.20 is enclosed:
☒ Large entity (\$110.00)

Respectfully submitted,

Judy M. Mohr

Judy M. Mohr
Registration No. 38,563

Date: 10/21/99

Correspondence Address:

Dehlinger & Associates
P.O. Box 60850
Palo Alto, CA 94306
Phone: (650) 324-0880